Sanofi (SNYNF.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Event Tracking

Dec23

Sanofi's efdoralprin alfa receives orphan drug designation for treating AATD-related emphysema

14:53

Sanofi's Wayrilz Approved by European Commission to Treat ITP

14:07

Sanofi and Regeneron Obtain Approval for Dupixent for Severe Asthma in Children Aged 6 to 11 from Japan's Ministry of Health

06:00

Dec22

Sanofi Reaches Agreement with US Government on Lowering Drug Prices

17:26

Berenberg cuts Sanofi target price

09:08

Dec19

Sanofi Reaches Agreement with US Government to Lower Drug Costs and Promote Innovation

19:41

Schedules & Filings

Schedules

Filings

Jan29

Earning Release(EST)

FY2025 Q4 Earning Release

Oct24

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 15.45 B, Net Income 3.286 B, EPS 2.6976

Jul31

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 12.57 B, Net Income 4.612 B, EPS 3.7893

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change